跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NUBEQA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
NUBEQA
Authorized
STANDARD
NUBEQA
Bayer Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
87ec3bc71f79521f
Company
Bayer Inc
Type
Standard
Approval Details
Approval Id
87ec3bc71f79521f
Drug Approval Canada Name
NUBEQA
Product Name
NUBEQA
Status
Marketed
Status Date
2020-03-24
Original Market Date
2020-03-24
Din
02496348
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L02BB06 DAROLUTAMIDE
Atc Name
l 02 bb 06
Aig Number
0162034001
Company Name
Bayer Inc
Company Address
2920 Matheson Blvd East, Mississauga, Ontario, Canada, L4W 5R6
Active Ingredients
DAROLUTAMIDE
300 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
87ec3bc71f79521f
Type
Standard
Back to Health Canada Approvals